"Short term relapse risk after switching from natalizumab to ocrelizumab or cladribine – an international cohort study (1712)." Neurology
96.15 Supplement
(2021):
1712.
Web. 05 Dec. 2023.
Advertisement
The most widely read and highly cited peer-reviewed neurology journal
